NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis $0.33 -0.04 (-10.35%) Closing price 04:00 PM EasternExtended Trading$0.33 +0.00 (+0.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Heron Therapeutics Stock (NASDAQ:HRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Heron Therapeutics alerts:Sign Up Key Stats Today's Range$0.32▼$0.3850-Day Range$0.27▼$0.5152-Week Range$0.26▼$1.58Volume2.32 million shsAverage Volume2.39 million shsMarket Capitalization$62.97 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company Overview Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing medicines for acute care and oncology-related supportive care. The company’s products are designed to address patient needs in areas such as postsurgical pain and chemotherapy-induced nausea and vomiting. Heron’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postsurgical pain, and APONVIE, an injectable formulation of aprepitant used to help prevent postoperative nausea and vomiting. The company also markets CINVANTI, an intravenous formulation of aprepitant used as part of regimens to prevent chemotherapy-induced nausea and vomiting. Heron’s marketed products are primarily commercialized in the United States through healthcare providers and institutions. The company is headquartered in San Diego, California, and has historically focused its research, development and commercialization activities on therapies intended to improve outcomes and experiences for patients undergoing surgery or cancer treatment.AI Generated. May Contain Errors. Read More Heron Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreHRTX MarketRank™: Heron Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 568th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingHeron Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and 1 sell rating.Upside PotentialHeron Therapeutics has a consensus price target of $2.00, representing about 503.0% upside from its current price of $0.33.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Heron Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.14) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 4.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Heron Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.33% of the float of Heron Therapeutics has been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 27.84, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 3.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.29 News SentimentHeron Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Heron Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.10% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heron Therapeutics' insider trading history. Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRTX Stock News HeadlinesHRTX Pro Research (inglés)September 30, 2026 | es.investing.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of "Hold" from BrokeragesSeptember 30, 2026 | americanbankingnews.comNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire year. The top five hyperscalers, Amazon, Google, Microsoft, Meta, and Oracle, are projected to spend 800 billion on AI this year and 1.3 trillion next year. Jason Bodner, a former Wall Street trader whose system has flagged stocks like Nvidia, Super Micro Computer, and Vertiv before major run ups, says a new light speed technology called Accelerated AI could be next in line for that spending.October 6 at 1:00 AM | Brownstone Research (Ad)Heron Therapeutics firma un accordo di licenza multi-prodotto con Long GroveSeptember 29, 2026 | it.investing.comHeron (HRTX) Q2 2026 Earnings Call TranscriptAugust 17, 2026 | finance.yahoo.comHeron Therapeutics Extends Tax Benefit Preservation Plan TimelineAugust 14, 2026 | tipranks.comHeron outlines covenants through 2027 and pro forma cash of $24.3M after September debt paymentAugust 11, 2026 | seekingalpha.comHeron Therapeutics Announces Second Quarter 2026 Financial ResultsAugust 11, 2026 | markets.businessinsider.comSee More Headlines HRTX Stock Analysis - Frequently Asked Questions How have HRTX shares performed this year? Heron Therapeutics' stock was trading at $1.30 at the beginning of the year. Since then, HRTX stock has decreased by 74.5% and is now trading at $0.3317. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) posted its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.03. The biotechnology company had revenue of $37.67 million for the quarter, compared to analysts' expectations of $42.19 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 293.02% and a negative net margin of 22.52%. Read the conference call transcript. Does Heron Therapeutics have any subsidiaries? Heron Therapeutics subsidiaries include Heron Therapeutics B.V.. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings8/10/2026Today10/06/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 HRTX's financial health is in the Red zone, according to TradeSmith. HRTX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HRTX CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees128Year Founded1983Price Target and Rating Average Price Target for Heron Therapeutics$2.00 High Price Target$2.00 Low Price Target$2.00 Potential Upside/Downside+503.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.19 million Net Margins-22.52% Pretax Margin-22.52% Return on Equity-293.02% Return on Assets-10.00% Debt Debt-to-Equity Ratio24.35 Current Ratio2.49 Quick Ratio1.51 Sales & Book Value Annual Sales$154.90 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book4.74Miscellaneous Outstanding Shares189,850,000Free Float178,271,000Market Cap$62.97 million OptionableOptionable Beta1.62 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:HRTX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
